We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 22 JULY 2015
Federal Circuit Finds Biosimilar Patent Dispute Resolution Procedures Optional
Foley & Lardner LLP
In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act (BPCIA), and did so in a manner that appears to favor biosimilar applicants over owners of original biologic products ("reference product sponsors").
United StatesIntellectual Property








